Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Ptc Therapeutics (PTCT) over the last 10 years, with Q3 2025 value amounting to $151.2 million.

  • Ptc Therapeutics' Non-cash Items rose 38919.3% to $151.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.2 million, marking a year-over-year increase of 38919.3%. This contributed to the annual value of $63.7 million for FY2024, which is 73308.63% up from last year.
  • Ptc Therapeutics' Non-cash Items amounted to $151.2 million in Q3 2025, which was up 38919.3% from $78.4 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Non-cash Items peaked at $151.2 million during Q3 2025, and registered a low of $5.3 million during Q2 2021.
  • In the last 5 years, Ptc Therapeutics' Non-cash Items had a median value of $30.9 million in 2024 and averaged $41.1 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Non-cash Items crashed by 9265.11% in 2022, and later surged by 99232.96% in 2025.
  • Over the past 5 years, Ptc Therapeutics' Non-cash Items (Quarter) stood at $50.6 million in 2021, then plummeted by 84.62% to $7.8 million in 2022, then dropped by 1.59% to $7.7 million in 2023, then soared by 733.09% to $63.7 million in 2024, then skyrocketed by 137.2% to $151.2 million in 2025.
  • Its Non-cash Items stands at $151.2 million for Q3 2025, versus $78.4 million for Q2 2025 and $6.5 million for Q1 2025.